期刊
MOLECULAR ONCOLOGY
卷 15, 期 6, 页码 1622-1646出版社
WILEY
DOI: 10.1002/1878-0261.12901
关键词
CTC enrichment; drug selection; microfluidics; molecular profiling; precision oncology; tumor resistance
类别
资金
- Canadian Institutes of Health Research [FDN-148415]
- Natural Sciences and Engineering Research Council of Canada [201606090]
- Province of Ontario though the Ministry of Research, Innovation and Science [RE05-009]
- National Cancer Institute of the National Institutes of Health [1R33CA204574]
Analysis of circulating tumor cells provides valuable insights in precision oncology, revealing associations between CTCs molecular profiles and tumor response to therapy. However, current limitations hinder the widespread clinical implementation of CTCs, suggesting the need for further research and advanced technologies.
Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of precision oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the molecular profiles of CTCs and tumor response to therapy. In this Review, we discuss mechanisms of tumor resistance to therapy and their link to phenotypic and genotypic properties of CTCs. We summarize key technologies used to isolate and analyze CTCs and discuss recent clinical studies that examined CTCs for genomic and proteomic predictors of responsiveness to therapy. We also point out current limitations that still hamper the implementation of CTCs into clinical practice. We finally reflect on how these shortcomings can be addressed with the likely contribution of multiparametric approaches and advanced data analytics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据